Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Insulin Manufacturers Ensure Stable Supply of Their Products
March 28, 2011
- Astellas Applies for Marketing Approval for Bixalomer
March 28, 2011
- Domestic, Foreign Drugmakers Up Efforts to Assist Quake Victims
March 28, 2011
- Wholesalers Striving to Fulfill Mission despite Risk
March 28, 2011
- Exal Approved for LCH as Additional Indication: Nippon Kayaku
March 28, 2011
- 2 Treatments Recommended for Approval as Senshin-iryo
March 28, 2011
- Gas Shortage Hurting Distribution in Tohoku: Wholesalers
March 28, 2011
- Higher Dosage Approved for Meropen: DSP
March 28, 2011
- Conditional Approval Recommended for Use of Epogin for Myocardial Infarction as Kohdo-iryo
March 28, 2011
- NEW PRODUCTS
March 28, 2011
- DSP to Collaborate with Kyoto Univ. in Cancer Field
March 28, 2011
- Sanko Junyaku to Market RDKK's Cobas h 232 Series from April
March 28, 2011
- Nippon Shinyaku Aims at Sales of ¥5.2 Bil. for Vidaza
March 28, 2011
- TS-1 Approved for Advanced Stomach Cancer in Europe: Taiho
March 28, 2011
- Daiichi Sankyo to Promote MEMARY Both in 1st Line Therapy and Combination
March 28, 2011
- Japanese Market for Antimicrobials to Contract to US$3 Bil. in 2019: Datamonitor
March 28, 2011
- Baxter's PREFLUCEL Approved in 13 EU Countries
March 28, 2011
- Operations Remain Suspended at Many Drug Production Facilities 1 Week after Disaster
March 28, 2011
- Nomura Securities Expects Peak Sales of ¥130 Bil. for Latuda
March 28, 2011
- Chuikyo Meetings to Be Postponed Due to Disaster
March 28, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…